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Abstract: The increasing availability of high throughput proteomics data provides us with
opportunities as well as posing new ethical challenges regarding data privacy and re-identifiability
of participants. Moreover, the fact that proteomics represents a level between the genotype and the
phenotype further exacerbates the situation, introducing dilemmas related to publicly available data,
anonymization, ownership of information and incidental findings. In this paper, we try to differentiate
proteomics from genomics data and cover the ethical challenges related to proteomics data sharing.
Finally, we give an overview of the proposed solutions and the outlook for future studies.
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1. Personal Genomics and Proteomics
Current discussions and regulations regarding high throughput, molecular level (OMICS) data
center around two seemingly opposite values. On the one hand, there is the duty of the researcher to
protect the research participants’ integrity and privacy, on the other hand, there is a scientific imperative
to share data with other researchers. Indeed, the technological and scientific transformation we are
experiencing in the era of high throughput OMICS technologies, is partially attributed to the sharing
of research data across studies, institutes and international borders. Thus, it has become the norm
for many data types generated via genomics and other high-throughput technologies, to make study
information widely and effectively accessible. This very fundamental principle of data sharing allows
the scientific community to be transparent and the scientific process to be reproducible and accountable.
The technological and ethical challenge is that this sharing of data involving human participants must
be performed in a way that adequately protects the interests of the participants.
We are living in the era of data economy where personal data (in any form) can be traded, mined,
analyzed and used for commercial or other gains. Recent scandals regarding the use of personal data
of individuals that were unaware of this (e.g., the Cambridge Analytica case [1]), and the fact that
evolving technologies question the idea that genomic data can be truly anonymized, poses a threat to
the principle of privacy. Proteomics data is considered relatively safe for sharing traditionally, but
today it consists of an ever larger amount of sequence information; this to an extent that is similar to
genomic level data, where anonymization and privacy is recognized to be absolutely crucial.
Here, we want to go beyond the issues associated with genetic and genomic research, and
demonstrate that in the field of proteomics, a thorough reflection on the aforementioned issues is
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imminent since precision medicine, relying heavily on various kinds of OMICS data, is rapidly changing
the future of diagnostic and therapeutic practices. Although most of the discussions in the public
domain are on genomic data, biological entities (like cells, tissues and organs) interact with their
environment through proteins, RNAs and metabolites, and not directly via its genome. The genotype
is relatively fixed and knowledge of the genotype translates itself into risk percentages for certain
diseases that can develop throughout a person’s life. However, proteins (in the form of transcriptomics,
proteomics and peptidomics) provide more biologically relevant information on the current state of
the phenotype. An in depth analysis of the transcriptome, proteome and metabolome can be regarded
as a more precise molecular phenotype (called proteotype in the case of proteins [2]) that can enable
detection of diseases and disease states other than solely genetic diseases. Furthermore, gene, protein
and metabolite level data analyses can also provide complementary approaches that can be linked
across data sources [3] and integrated at the systems level. One example is the usage of clinical
biochemistry, proteomics and metabolomics signatures to determine personal disease risk profiles
using (combnations of) biomarkers. Another application is pharmacoproteomics, where the effects of
drugs on protein levels are monitored [4]. Proteomics also provides crucial knowledge in fundamental
research of disease aetiology and can therefore aid the translation of basic research into therapies in a
supportive or leading role. Lastly, the information content related to a coding gene increases during
its expression and function (due to processing, modifications, cellular location, etc.) and proteomics
can provide information on these aspects [5], which is relevant since these modifications are often
dysregulated in disease.
Proteomes can also be acquired on the cellular up to the systemic level (organs, blood, urine and
cerebrospinal fluid) and can therefore represent their origin, which makes proteomics indispensable in
precision medicine. Proteomics is therefore not only a “watered-down” version of genomics privacy
wise but in addition contains information on a person’s phenotype. Therefore, it should be treated
with care and also presents new idiosyncratic challenges for its use in personalized medicine.
2. Proteomics as Sensitive Data
Genomic data is conventionally recognized as strictly personal and it is currently under debate if it
even is possible to anonymize it (see further) [6]. However, it is not yet clear to what extent proteomics
and metabolomics data require the same status. Metabolites, as an end-product of metabolic pathways,
can probably be considered non-personal except for rare metabolic syndromes. This discussion refers to
the proteomics characterization by use of mass spectrometry (MS), since this technique relies on peptide
sequencing (e.g., instead of the use of antibodies in multiplexed ELISAs), resulting in a representation
of the genome. Antibody based chips are usually not directed against peptides with single amino
acid variations, unless they are specifically designed to do so. Proteomics is currently treated as
non-personal data in the scientific community (e.g., by the National Cancer Institute, US). This opinion
is historically based on the fact that, until the advent of the new generation of mass spectrometers (and
bioinformatic methods), the depth at which proteomes are charted is limited compared with genomics.
However, as mass spectrometers become more sensitive and faster, the percentage of the sequence
information that can be obtained through proteomics increases. Additionally, there is a necessity to
verify the experimental workflows in proteomics since these are more prone to experimental errors
when compared to genomics and open access to the unprocessed data is often required by scientific
publishers to preserve the integrity of data quality. The privacy risks in proteomics need to be clearly
reviewed and working solutions have to be proposed; e.g., the design of a data format that does not
contain sensitive and/or personal proteomic information but still informative enough for research when
made available to third parties. Another pertinent question is how much phenotypical information
(such as disease/risk status) on a subject is associated with the proteomic profile. Proteomics can
therefore be twofold sensitive: It can identify people and provides clues about their health.
A typical proteomics pipeline contains more steps than genomics and the eventual data from
proteomics is multilevel. Genomics provides genetic sequences while proteomics can produce partial
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peptide sequences, peptide identifications, protein identifications (with the corresponding protein
coverage, i.e., how much of the protein is covered by peptide identifications), modification profiles,
quantification and pathway level information. This can all be extracted from the raw data obtained
with a mass spectrometer. We will discuss raw proteomics data and specify the data level and type
when necessary. For example, identification strategies that use single amino acid polymorphisms
(SAPs) can use raw and unfiltered peptide level data, whereas protein IDs and quantification metrics
will not be regarded as identification (but not health) sensitive data.
Allelic variants in the genome can only propagate to the proteomic level if they are in coding
regions (disregarding the more complex question on how these alleles can quantitatively influence
protein expression) and if they result in an amino acid substitution that is not isobaric (e.g., a leucine to
isoleucine conversion cannot be detected in standard proteomic experiments), these are called SAPs [7].
There were roughly 1.1 × 106–1.3 × 106 SAP reported in 2016 [7]. This number is probably much lower
in the genome of a person since it contains mutations from cancer genomes that generally cannot
be used for identification purposes. Parker et al. estimated that there are more than 35 × 103 non
synonymous single nucleotide polymorphisms (nsSNPs) in exosomes with frequencies over 0.8% [8].
Mutations that alter protein splicing and deletions that cause frame shifts can also occur but are less
frequent. Proteomic pipelines can identify all these events with or without using matched genomic
data (from genomics or transcriptomics); those using it being the more accurate and sensitive. In
proteomics, proteins in a sample are usually identified by enzymatically cleaving the protein and
analyzing the resulting peptides since peptides are inherently much easier to measure and identify
than full-length proteins (this rationale is called bottom-up proteomics). The digestion step results in a
highly complex peptide mixture and there is therefore a need to separate the peptides before entry
into the mass spectrometer. Liquid chromatography is the most used peptide separation method. The
standard proteomics LC–MS method is data-dependent acquisition (DDA), where the masses of the
eluting peptides are measured (MS1) and selected for fragmentation one by one. Fragmentation in the
MS (called MS/MS or MS2) generates fragmentation spectra that contain sequence information of the
peptide. Each fragmentation spectrum is associated with a mass of the intact proteolytic peptide, with
a list of masses of the fragments and method related information like retention time (time of elution).
These spectra can be queried by a variety of methods and tools to link the fragmentation spectrum to a
protein sequence translated from a genome. Protein databases can be cleaved in silico, after which
the theoretical mass of the parent peptide and the fragments are calculated (the retention time and
fragment ion intensities can also be predicted) and compared with experimental spectra. The selection
and isolation of peptides in the MS is a critical step: usually not all peptides can be fragmented due
to time constraints, they can be fragmented at sub-optimal points in their elution profile (resulting
in MS2 spectra with a low information content) and the isolation is not absolute, resulting in mixed
fragmentation spectra. All these factors hamper the clear delineation of the part of the proteome
that is “personal”. Data independent acquisition (DIA) aims to overcome some of these problems by
systematically selecting the whole mass range of MS1 for fragmentation in cycles [9]. This means that
the issues of selection timing and the semi-stochastic nature of selection are no longer a problem, but
this comes at the expense of highly convoluted spectra. These fragmentation spectra are a mixture of
all peptides eluting at a certain time from the LC in a window that can range from 2 to a few hundred
m/z. These spectra can be queried by looking for pre-defined transitions (a combination of parent and
fragmentation mass or m/z) or be deconvoluted and submitted to a DDA type search engine. The latter
is usually less sensitive since it does not use prior knowledge.
There are several ways to detect SAPs in proteomics. The sequence of a peptide can be determined
directly from its fragmentation spectra without using any other information. This is called de novo
sequencing and requires high quality spectra. The full sequence is usually not possible but short
tags (called peptide sequence tags, PSTs) can be identified. For pure de novo (de novo can be
integrated in database searches), the nsSNP has to be in a region where fragments are detected.
Full fragment coverage is not necessary (a mass shift due to a combination of amino acids can still
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be reliably determined, although the order is unknown in that case) but is beneficial for de novo
sequencing. Database searches in general can only identify peptides that are contained in the database
(like dbSAP, [7]). The search space of search engines increases with larger databases, and this can
hamper efficient identification of SAPs. Open modification (or error tolerant) searches can also be
used [10] but suffer from the same problem (unless they are combined with e.g., spectral matching
in hybrid approaches [11]). An optimal search space is acquired by using custom transcriptomics
or RiboSeq based protein databases [12]. Database searches can identify more peptides than pure
de novo approaches since the prior knowledge lowers the amount of evidence needed for a positive
identification. However, it is always advisable to systematically double check modifications and
mutations if a very large search space is used. DIA systematically searches for fragment ions that are
unique for a peptide in a convoluted spectrum. Fragments and transitions that specifically define a
SAP have to be included in the search in order to be able to detect them [13].
However, DIA as well as DDA data can be re-queried with databases that contain SAPs or SAP
specific transitions. Especially DIA is well suited for re-analysis since it contains in principle fragments
of all detectable peptides, including their elution profile. DDA data can also contain “cryptic” fragments
in mixed spectra.
DDA and DIA are both screening methods that are not hypothesis driven. Targeted proteomics,
where only a limited number of proteins (maximal a few hundred) are measured, is an alternative
hypothesis based strategy. For each protein, a few well responding peptides are selected, and from
these proteins a few (selected reaction monitoring or SRM) or all (parallel reaction monitoring or PRM)
transitions are measured. These methods have inherently a low chance of picking up SAPs, unless they
are specifically designed for them [14]. SRM has the lowest sensitive information content, followed by
PRM, DDA and DIA.
Several fields in proteomics are currently interested in detecting SAPs. Especially proteogenomics
deals with this, where the most developed field is oncoproteogenomics since tumor mutations are
of particular interest in fundamental and diagnostic cancer research [15–17]. On a practical note, the
International Cancer Genome Consortium has established that although it should largely treat the
non-cancerous sequencing data as personal data, genetic variants specific to tumor cells are nonetheless
anonymous, with only rare exceptions. Hence they freely distribute the anonymous variants to
other researchers in accordance with the principle of open science. Another remark is that many
nsSNPs that have a physiological effect are altering the protein modification profile (post-translational
modifications or PTMs), for example new phosphorylation or ubiquitination sites. PTM specific
techniques (phosphoproteomics being the most widely used) can therefore enrich SAPs in the sample.
Related to oncoprote(ogen)omics is immunopeptidomics, where the peptides presented by the antigen
presenting MHC1 and MHC2 complexes are analyzed. The aim of these studies is often to determine
which peptides could possibly be used to train immune cells to combat diseases such as cancer [18].
Of course, the exact peptide sequence is of utmost importance when investigating possible antigens.
In oncology, of high interest are the mutation-derived neoantigens released by cancer cells that can
initiate an anti-tumor immune response. A third field is the search for proteins that remain undetected
by proteomics methods [19–21]. There can be several reasons for the lack of proteomic evidence of
proteins and sequence variation, including the absence of the correct sequence in the database, is one
of them. Evidently, reanalysis of the unidentified spectra can be an efficient strategy to identify SAP
containing peptides. Finally, the use of proteomics in forensic sciences is currently being explored and
initial reports that try to identify people using proteins in hair, bone and epidermal cells found in
fingerprints indicate that the approach is valid [8,22–24]. The technical challenges of SAP detection,
and validation, in the aforementioned fields are met with increasingly more refined and powerful
bioinformatic tools, like spectral libraries [25], specialized databases [26–29], pipelines for quality
control [19,21,30,31], and more recently, fragment intensity prediction software that is incorporated in
DDA and DIA search engines [32,33]. SAPs can now be detected and quantified from 100 µg of serum
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proteins [34], used to discriminate cancer patients from healthy individuals and can be detected in a
handful of cells [35].
A person can be identified by the combination of their nsSNPs. The likelihood of a positive
identification can be calculated by multiplying the frequencies of the allele corresponding to the nsSNP.
Li and colleagues used only the minor allelic frequencies of nsSNPs and adjusted the likelihood of
identification by the global peptide false discovery rate [36]. The analysis proved that enough nsSNPs
from minor alleles can be detected in serum/plasma (up to 20) for identification, and this minimal
requirement of SAPs will soon pose even less of a problem since the performance of LC–MS systems
is increasing rapidly. The study also already pointed out some of the peculiarities of proteomics
compared to genomics data. First of all, proteomics data is a subsample of the genome and the amount
of identifiable data depends on the sample. Second, an additional layer of uncertainty is connected
to peptide identifications, as every single peptide identification has a probability value attached to it
and highly significant SAP identifications can be weighed more than less significant identifications.
DDA, DIA, PRM and SRM all have theoretical frameworks to control the false discovery rate and have
methods to assign confidence to a particular identification in an experiment. Third, the bioinformatic
identification stage is the main cause of differences in interlaboratory reproducibility (hence the need
for submission of data to public repositories). Various software approaches for SAP detection will give
different results, and the overlap and differences in results will influence identification likelihoods.
For example, results from DDA search engines do not completely overlap and identification results
from DIA (when using transition lists) can vary depending on used spectral library. Some of these
additional layers of complexity are currently being addressed by the scientific community and soon
will open the path towards proteomics as a mature complement of the genomic data which warrants
premeditation when sharing and integrating proteomics data with other data repositories.
The General Data Protection Regulation (GDPR) came into effect in 2018 in the European Union.
Genetic data is defined in the GDPR as “personal data relating to the inherited or acquired genetic
characteristics of a natural person, which result from the analysis of a biological sample from the
natural person in question, in particular chromosomal, deoxyribonucleic acid (DNA) or ribonucleic
acid (RNA) analysis, or from the analysis of another element enabling equivalent information to be
obtained”. Proteins provide equivalent information of genetic data, as discussed above, and as such
are also genetic data. It even means that the likelihood of “real world” identification, for example
by linking SAPs to genetic data in (formerly) available repositories and having a strong link to an
existing person, is not required to classify it as personal data. If the data can theoretically be used for
identification purposes, it is considered personal genetic data, even if there are practical challenges that
impede a researcher of directly doing so. However, this does not mean that proteomics data cannot be
practically anonymized (see further).
Additionally, the GDPR also considers health related data as sensitive. SAPs can give a first look
into a person’s health if they are associated with nsSNPs that have a known corresponding genetic risk
factor. There is also an increasing list of protein biomarkers for various diseases. These biomarkers are
usually measured with ELISAs or related antibody based technologies since absolute and accurate
quantification of biomarkers with LC–MS can be a tedious process, but possible nonetheless. For
example, a comparison between protein immunoprecipitation MRM (multiple reaction monitoring, a
form of targeted proteomics) and ELISA has shown that there is a high correlation between both [37].
For some biomarkers, LC–MS based methods are actually preferred, as in the case of the various forms
of amyloid β that are difficult to distinguish with antibodies [38]. There is also a recent trend in LC–MS
based quantification where relative and absolute quantifications are combined [39], which could be
very useful in biomarker research. Lastly, the predictive status of proteomic profiles is currently
being explored: Can we correlate phenotypes with proteomics data across experiments instead of
just focusing on one or a small set of proteins? If so, this would indicate that the proteomics profile
of clinical matrices could be used to infer the health status of a person. The advent of personalized
medicine and the use of proteomics herein, will probably stimulate these developments.
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3. Ethical Issues in Personal Proteomics Research
The gathering of large amounts of data that are necessary for a systems biology approach to
personal medicine creates specific ethical questions. Much has already been written regarding issues
related to (genetic) biobanking and genetic research [40,41]. For example, current discussions focus on
the right to genetic privacy of research subjects and of patients donating samples for genetic research.
Whereas ten years ago, the ethical and legal discussions on genetic privacy focused primarily on
whether samples and data should be anonymized, coded or identifiable, and how such biobanks had
to be governed [42], today the challenges of whole genome sequencing and the idea that it may be
impossible to completely anonymize DNA are discussed [6]. Other discussions center around the
right of participants to receive information about their DNA that is used in research, or the duty of
researchers or even clinicians to return incidental findings that may or may not be of some clinical
utility to the patients or research subjects [43]. In genetic research, ethical frameworks regarding
consent (can participants give blanket consent? Is consent needed even for leftover samples?) and
solidarity (is strict consent needed if the research benefits society?) were already proposed [44]. The
discussion on the ethical aspects of proteomics can be picked up by the current discussion on genomics
data and biobanking. We would like to emphasize that it will most likely not be possible to have one
answer that would fit all situations (and study conditions) but an internationally recognized set of
ethical guidelines to follow up would be a step forward. This would potentially assist the ethical
committees advising personalized medicine and clinical proteomics studies.
Anonymization and identifiability with regard to genetic samples is a broadly covered topic, but
proteomics may raise some new specific questions. As we described above, it may be possible to
obtain DNA information from proteins, which would immediately make all the ethical issues related to
genetic research also relevant for proteomics. Moreover, the fact that also phenotypic information may
be deduced from proteomics, makes this issue even more pertinent. Indeed, one of the reasons why
privacy is important with regard to such information is the possibility that this information is misused
by third parties such as employers and insurers. For the purposes that they would be interested in,
phenotypic information is more interesting than genotypes alone.
One of the solutions that was proposed to avoid problems related to privacy and confidentiality
is complete anonymization of samples. Anonymization is the irreversible alteration of any type of
personal data so that its human subjects are no longer identifiable. This process is incompatible
with longitudinal follow-up, and is therefore generally discouraged in precision medicine. It is
understandable that anonymization is seen as an attractive option to comply with data protection laws.
Indeed, the GDPR does not seek to regulate anonymized data, while insisting on keeping data in an
identifiable form for no longer than necessary for the purposes for which it is processed.
So far when it comes to genomics level data GDPR links the assessment of identifiability to
available technology where all attempts on anonymization fell short by the next available technology.
First it was shown by Gymrek and colleagues [45] that it was possible to identify people with their
surnames based solely on their DNA and trace amounts of associated metadata. They have concluded
that even a few markers from one person can spread through deep genealogical ties and lead to
the identification of another person who might have no acquaintance with the person who released
their genetic data. Another feature of their identification technique was that it relied entirely on free,
publicly available resources, which can be executed with only computational tools and an Internet
connection. The identification is proven to be possible even if the amount of information was as small
as 25 randomly selected loci from the whole genome [46]. This number of loci can already be achieved
by current proteomic technologies, as was discussed, and results from this study can therefore be
extrapolated to proteomics. Further complicating the situation is that it was demonstrated to be possible
to accurately and robustly determine whether individuals DNA are present in a complex genomic
DNA mixture [47]. Although this technology could potentially be very useful in forensic science it
hampers the efforts to make the efforts of aggregate genomic data (such as GWAS) publicly available.
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Genomic data-sharing beacons provides an easy to implement, standardized and secure solution
for genomic level data-sharing by explicitly allowing yes/no queries on the presence of specific alleles
in the beacon content. Previously deemed secure against re-identification attacks, beacons are also
very recently demonstrated to be vulnerable despite their very stringent policy. Although the risks are
not comparable to identification of individuals with their surnames, recent studies have demonstrated
that it is possible to determine whether a person is in the dataset, by repeatedly querying the beacon
for his/her single-nucleotide polymorphisms (SNPs) [48].
In spite of this situation, we believe it is still premature to conclude that genomic data cannot
be anonymized, and a fortiori the impossibility to anonymize proteomic data especially since the
end-product of a proteomics pipeline is highly processed. For the moment, it is unsure whether raw
proteomics data can be fully anonymized. However, the various levels of proteomics data can provide
more opportunities for anonymization than genomics data (see below). We believe therefore that
participants in future personalized medicine studies including proteomics should be informed about
new evolutions regarding identifiability of proteomics (and genomics) samples themselves. An open
communication regarding this issue with research participants is warranted, as this will help build
trust. A reason why complete anonymization of samples may be problematic (from an ethical point) is
the fact that certain health information that is relevant to the research participants themselves may be
discovered. How to deal with these incidental findings has been a hot topic in the debate regarding
genomic data and the question will be even more pertinent in proteomics.
All matters become even more complicated when studies integrate various data from genetic
testing, clinical markers (epigenetics, proteomics and metabolomics) and state of the art sensors, as is
done increasingly to monitor people’s health. A typical use of proteomics in such endeavors is the
longitudinal follow up of urine or various types of blood samples. Such varied forms of data can
provide insight in (a) health risks related to genetic, environmental and behavioral factors, (b) insights
in molecular mechanisms associated with disease and (c) possible leads for new therapies. However,
the data obtained also generates even more privacy issues concerning a person’s health. This poses
even harder ethical, practical and legal challenges. It will be possible to determine personal health
risks (for instance based on an individual’s genetic profile) while, at the same time, monitor changes in
molecular pathways associated with these health risks. Although this opens up the possibility to go to
a system of personalized prevention, it also creates an urgent need to establish an ethical framework
for such studies that will try to tackle problems associated with the use of these technologies and the
results they will produce. In these cases, a framework needs to be established in which participants
can be informed on actions to improve health or prevent disease. An important part of this ethical
framework will pertain reporting (non-)incidental findings and risk factors. Increased knowledge of
one’s health can increase the mental burden of being responsible for one’s own health, but risk factors
and lifestyle recommendations should be balanced by the best knowledge on their effectiveness.
4. Consent
Issues related to data privacy, and the return of results, should be clearly communicated in consent
forms. Asking consent from research participants should not solely be seen as a means to protect
against legal claims, but also as a means to generate and maintain openness about the research, and
hence to enable trust in research. As such, it is an acknowledgement of the fact that participants may
have an opinion on what kind of research is done, and that their opinion matters. The scope, scale and
duration of large-scale proteomics studies requires the development of new technologies, technological
implementations and ethical recommendations concerning consent of people for collecting, analyzing
and sharing their data. The medium (e.g., electronic) and clear language of the consent is very
important. GDPR states that broad consent has to be avoided but repeated requests for approval
can lead to “consent-fatigue”. In addition, due to cohort-size, sampling frequency and data types
and density, acquiring specific consent for follow-up or additional studies can soon become very
complicated. A workable solution, legal, technical and ethical, of obtaining additional consent from
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participants for new analysis has to be worked out. An example is dynamic consent, using an electronic
platform that minimizes the effort of both asking and receiving consent to a minimum. We envision
that different consent mechanisms for academic research and economic valorization will be required.
In the case of economic valorization, reward mechanisms for the participating individuals (if target
participant numbers are reached) could be coupled to form a feedback mechanism that will result in a
sustainable ecosystem.
5. Current Precautions and Possible Working Solutions
The amount of personal health data is increasing at a fast pace and the value of such aggregated
data has been recognized by commercial entities (such as Google’s Verily Life Sciences, Mountain
View, CA, USA; 23andMe, Mountain View, CA, USA; Nebula Genomics, San Francisco, CA, USA;
PatientsLikeMe, Cambridge, MA, USA, etc.). The last few years it has become apparent that there
are serious risks in terms of privacy and data safety in giving commercial companies unrestricted
access to not anonymized personal data. However, efficient use of integrated personal data can greatly
benefit both general health (including healthcare and pharmaceutical industry) and personal health.
One could make the claim that since the individual is the source and the owner of personal data,
if used in association with the individual identified, (s)he should also directly benefit from sharing
personal health data. Development of such future frameworks in personalized medicine would require
dynamic consent and coupled to rewarding mechanisms. These frameworks are already starting
to be developed in commercial companies that analyze genomic data. New standards on personal
data management need to be developed or implemented for these frameworks to fully mature. The
participant’s privacy needs to be safeguarded at all times, ensuring that true data ownership is with
the participant. Methodologies, knowledge and the aggregated (anonymized) data by itself can be
used for economic valorization. A business model that is fair to the participants is strongly preferred
(third party commercial access is reviewed on a case per case basis), and policies will have to be put in
place to ensure that the data shared with third parties cannot be re-identified or abused in other ways.
An important factor in the discussion is the ability to achieve true anonymization of health data,
proteomics included. In this scenario, the aggregated data would be a highly valuable economical
commodity whose ownership would be less obvious and traded and used more easily. The challenges
ahead are to determine the definition of sensitive and identifiable information within the proteomics
datasets and whether this information can be removed or made inaccessible without significantly
reducing the scientific quality.
The various levels of data in proteomics entail various levels of data sensitivity. Health related
data is only sensitive if it can be linked to a person. Fortunately, health related data can be largely
dissociated from peptide level data that can identify a person, so a first step in determining the
possibility of anonymization would be to delineate the research question and to determine which level
of proteomics data is needed and sufficient to answer it. Typical research questions can be:
• Is a protein detected in a dataset?
• Is the protein identification reliable?
• Is the PTM profile different between conditions?
• Are there different pathways upregulated between conditions?
• Is the statistical analysis supported by the data? For example, is the proposed biomarker indeed a
good candidate to discriminate healthy persons from diseased?
The main reason for open access in clinical proteomics and its application in personalized medicine
is the reliability of the bioinformatics workflows. This pertains the protein identification but, in the
case of quantitative proteomics also normalization and transformation of the data. Quantitative data
extraction can easily be done on known non-SAPs, having a reliable feature detection algorithm being
the only liability. Processed quantitative data can therefore be disseminated without privacy risks.
Likewise, looking for proteins in online datasets and PTM analyses can be processed and filtered
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to leave out SAPs. This means that only analyses directly involving detecting and reporting SAPs
in raw data should be scrutinized in assessing re-identifiability issues. Working towards consensus
identification and quantification pipelines would address parts of this problem.
Genetic data is not available to the public because of the obvious privacy reasons. The same is
true for genetic information in proteogenomics. The translated database used for querying, as well as
the identified SAPs can pose a risk. The only truly anonymous raw proteomics data is SRM, if the
measured transitions are not defined by an nsSNP. The security risk in PRM is present but can be
evaluated if there are SAP identifying transitions in the retention time and mass range of the peptide.
For DDA and DIA, the absence of privacy risks in raw data might never be fully guaranteed. One
solution proposed [36] was processing the raw data by removing fragmentation spectra of SAPs. This
is a reasonable solution, but not a conclusive one since there still can be fragmentation spectra from
SAPs that escaped detection due to software or, more probably, database issues. One could argue that
the remaining SAPs are too few and/or of too poor quality to conclusively pose identification risks, but
this remains to be investigated. Critselis E. recently proposed to submit batches of pseudonymized
data instead of individual data [49], but this would only work if the relation between the SAPs is
removed completely. This means that MS/MS spectra of all experiments would be submitted as a whole
(so processed data, not raw data), and the identifications and accompanying FDR estimations are done
experiment instead of sample wise. In this setup, the identification step and the quantification step can
be separated, but both could be made publicly available in an altered format that is anonymous. Of
course, the latter two proposals are DDA specific, since safely publishing sensitive DIA would require
even more processing.
Another option would be to implement search engines in proteomics repositories, and researchers
interested in investigating a privacy sensitive data set would perform their analyses on a server, where
after the results are filtered for SAPs. The availability of raw data on servers that is accessible to
other proteomics researchers after permission would not alter the original purpose of the research
(for which consent was given) and would be in the public interest since the reliability of proteomics
research is reviewed and monitored continuously. There are currently national computer clusters that
are dedicated to sensitive data and allow a federated analysis, like the Swedish Bianca cluster. Sweden
also has a local version of the European Genome–Phemome Archive (EGA-SE), which has restricted
access; e.g., as used in [50]. Open repositories could also have different access levels that allow us to
query all the data except for the sensitive. A filter for meta-analyses of open repositories would also
be an option. The reason for open repositories are stated above, and a stringent reviewing process
of clinical LC–MS data analyses by multiple third parties, as an additional qualitative part of paper
submission and reviewing, would increase the confidence in the conclusion of clinical proteomics
and partially counter the main reason for submission to open repositories. The practical feasibility of
these options, and other not proposed by the authors, will have to be discussed by the proteomics
community, since the last and least attractive option would be closed repositories.
Personalized medicine, with its various data formats (genomics, proteomics, metabolomics,
etc.), is a more challenging domain. Recently blockchain technology is being proposed [51,52] as
a distributed electronic ledger for hosting health information. Blockchain technology allows us to
create a distributed, transparent, independent and secure private information ledger where health
data providers (individuals) are in control, own their information and can monitor access privileges as
well as being informed about who accessed their information. Although, this technology is new in the
health domain and currently only realized by a single start-up (Genomes.io) [53,54], it has potential
for growth since it enables a data-driven marketplace to be created where users can receive tangible
benefits for making their data accessible and immutable to the research organizations, application
development community, pharmaceutical and consumer businesses. Blockchain alone does not
solve the re-identifiability problem, however it addresses the issue of consent while simplifying
and incentivizing data sharing in a secure and transparent manner. Currently the market leader
is the KSI® blockchain technology stack developed by Guardtime, which is being used by NATO,
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the US Department of Defense, Lockheed Martin, Boeing, Ericsson, Telstra, SAP, GE and in Estonia
where majority of the state data systems utilize the blockchain technology to enforce the integrity of
government data and systems. The application of blockchain technology for personalized medicine
(e.g., by the Estonian Genome Center, Tartu, Estonia) is currently being implemented.
6. Conclusions
A consistent increase in both depth (resolution) and size (population range) of proteomics studies
not only allows significant scientific progress but also poses ethical challenges regarding personal
privacy sharing for where reproducibility is a fundamental pillar in science, the fact that it may be
possible to deduce genomic information from proteomic data means discussions regarding privacy,
sharing of results and regulations that are applicable to genomics may also become relevant for
the proteomics field (not all researchers might be aware of this currently). Moreover, the fact that
proteomics represents a level between the genotype and the phenotype may introduce even more
intricate questions related to data access, ownership of information and incidental findings. We believe
that trust in research is a precious commodity to be protected. This means, on the one hand, that
researchers should be made aware of these potential issues. Researchers should know that existing
privacy regulations might also apply to proteomics research and be conscious about this when dealing
with proteomics data. On the other hand, research participants have the right to know about these
issues, both about what we know now and what we may know in the future. Consequently, consent
procedures may need to be revised from time to time and platforms for dynamic consent may be set up
to allow for smooth communication between researcher and participants.
Therefore we envision the next generation of scientific enterprise is a highly collaborative
environment where researchers recognize that they are entrusted with invaluable personal information,
and research participants feel their data is safe, where demands of open science and the need for data
protection are consolidated.
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